Last reviewed · How we verify
Glucose-insulin infusion
At a glance
| Generic name | Glucose-insulin infusion |
|---|---|
| Also known as | Glukose, Novorapid |
| Sponsor | University of Aarhus |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance (PHASE4)
- Polycystic Ovary Syndrome in Type 1 Diabetes
- Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes (PHASE2)
- Glycemic Targets During CPB in Elderly Diabetes (NA)
- Physical Activity to Prevent and Treat Hyperglycemia From a Mistimed Bolus Insulin Dose (NA)
- Abscisic Acid Effects on Glucose Homeostasis and Insulin Sensitivity (PHASE2)
- Two Way Crossover Closed Loop MPC vs Control IQ (NA)
- Two Way Crossover Closed Loop Study Insulin vs Insulin and Pramlintide (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glucose-insulin infusion CI brief — competitive landscape report
- Glucose-insulin infusion updates RSS · CI watch RSS
- University of Aarhus portfolio CI